I4J-MC-HHBD: A Phase I Trial of LY2940680 in Pediatric Patients with Recurrent or Refractory Rhabdomyosarcoma and Medulloblastoma.

Why are we doing this research?

The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment. The study will also explore the changes in a cancer marker levels. Finally, the study will help document any antitumor activity.

Who can participate?

Patients between the ages of 12 months to 21 years with medulloblastoma or rhabdomyosarcoma are eligible for this study. For further information on inclusion criteria, download or print the PDF for this study below. 


  • From 1 to 21 years old


  • Cancer - Brain and Spinal Tumors
  • Cancer - Musculoskeletal Tumors


  • Female
  • Male


For more information contact:

Cincinnati Children’s Hospital Medical Center
Division of Hematology/Oncology
3333 Burnet Ave., Cincinnati, OH 45229-3039
Phone: 513-636-2799